This study is looking at how a special imaging agent, called [18F]-FAPI-74, works in people with refractory dermatomyositis (a muscle disease that doesn't respond well to usual treatments). Researchers want to see how much of this agent is taken up by the body during a PET/MRI scan. You might be able to join if you are an adult over 18 with suspected dermatomyositis and are willing to give your informed consent. The study is not currently recruiting, and it plans to include 21 participants. The main goal is to measure the rate at which [18F]-FAPI-74 is absorbed in your body, which will be checked up to one hour after it's given.

Study design

This is a single-center, single-arm study, meaning all 21 participants will receive the same intervention. The study status is currently unclear.

What's involved

You would receive an intravenous (into a vein) administration of [18F]-FAPI-74 and undergo PET/MRI imaging.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, [18F]-FAPI-74 uptake, will be measured up to 1 hour after administration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.